Deucravacitinib for active Takayasu's arteritis
Treatments studied
Part of Heart & circulation, Skin clinical trials.
This trial tests an oral medication called deucravacitinib (which is already used for psoriasis) to see if it can calm inflammation in Takayasu's arteritis. If you have active disease despite current treatment, this may offer a new option to help control symptoms and prevent damage.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years old or older and have a confirmed diagnosis of Takayasu's arteritis.
- Your disease must still be active (or has flared) despite treatment with steroids plus another immune-suppressing drug.
- You should not have already tried and failed a TNF inhibitor (e.g., adalimumab) due to lack of effect or side effects.
- You must not have severe heart or brain involvement from the disease that needs urgent surgery.
- You must be free of active infections like hepatitis B, C, or TB, and have normal liver and kidney function.
- If you are a woman who could become pregnant, you must agree to use highly effective birth control during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing two new medications, vunakizumab and ivarmacitinib, to see if they are safe and effective at controlling active Takayasu's arteritis. These medicines work differently from your current treatment, so they might help reduce inflammation and prevent more damage to your blood vessels.
This study collects medical information from patients diagnosed with Takayasu arteritis, a rare disease affecting large blood vessels. By joining, you help researchers better understand this condition and improve care for future patients.
This study tests a new ultrasound scoring system to monitor disease activity in people with Takayasu arteritis. It aims to see if ultrasound can reliably track the disease, which might help guide treatment decisions.
This study collects information and blood samples (biomarkers) to better understand Takayasu arteritis and how active it is. It may help researchers find tests that support diagnosis and track disease activity.
This trial tests a drug called secukinumab to see if it can help people with severe Takayasu arteritis, a rare disease that causes inflammation in the blood vessels. The drug works by blocking a protein that drives inflammation, which may reduce disease activity and help people lower their steroid dose.
This trial studies treatment options for people age 14 and older with severe, active Takayasu arteritis causing major circulation problems and organ strain. It may help reduce inflammation and complications when the disease is flaring and difficult to control.
Hear when a new Takayasu Arteritis (TAK) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.